Pfizer Pushing Into Obesity Treatments with $4.9B Deal for Metsera

Five months after ending development of its own obesity treatment, Pfizer is accelerating its push into the rapidly growing field with a nearly $5 billion acquisition.

The COVID-19 vaccine and treatment maker said Monday that it will pay $47.50 in cash for each share of development-stage drugmaker Metsera. That represents a premium of more than 42% to Metsera’s closing price Friday.

Pfizer also could pay an additional $22.50 per share depending on how Metsera’s product pipeline develops.

Read more at AP News